C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
BlackOPs: increasing confidence in variant detection through mappability filtering
Christopher R. Cabanski,Matthew D. Wilkerson,Matthew G. Soloway,Joel S. Parker,Jinze Liu,Jan F. Prins,James Stephen Marron,Charles M. Perou,D. Neil Hayes +8 more
TL;DR: Accounting for mapping-caused variants tuned to experimental setups reduces false positives and, therefore, improves genome characterization by high-throughput sequencing.
Journal ArticleDOI
The association between copy number aberration, DNA methylation and gene expression in tumor samples.
Wei Sun,Paul Bunn,Chong Jin,Paul Little,Vasyl Zhabotynsky,Charles M. Perou,David N. Hayes,Mengjie Chen,Danyu Lin +8 more
TL;DR: It is suggested that SCNA often affect DNA methylation and gene expression independently, while the CpGs with negative/positive associations with SCNA are often located around CpG islands/ocean, respectively.
Journal ArticleDOI
Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53.
TL;DR: In this article, a large-scale immunoprecipitation of Mdm2 in the osteosarcoma U2OS cell line was performed to identify novel binding partners, and a significant binding protein identified was Hep27, a member of the short-chain alcohol dehydrogenase/reductase (SDR) family of enzymes.
Journal ArticleDOI
Association between breast cancer subtypes and response to neoadjuvant anastrozole
Anita K. Dunbier,Helen Anderson,Helen Anderson,Zara Ghazoui,Zara Ghazoui,Janine Salter,Janine Salter,Joel S. Parker,Charles M. Perou,Ian E. Smith,Mitch Dowsett,Mitch Dowsett +11 more
TL;DR: The results suggest that in the short-term, Luminal A and B tumours may gain similar benefit from an AI but that the higher residual Ki67 level seen in Luminal B is indicative of poorer long term outcome.
Journal ArticleDOI
Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer.
TL;DR: A possible tumor suppressor role for the c-Myb proto-oncogene in breast cancer is described, for the first time, that has implications for the understanding of luminal tumorigenesis and for guiding treatment.